首页> 外文学位 >Optimizing immunity against BCR-ABL positive leukemia.
【24h】

Optimizing immunity against BCR-ABL positive leukemia.

机译:优化针对BCR-ABL阳性白血病的免疫力。

获取原文
获取原文并翻译 | 示例

摘要

Chronic myelogenous leukemia (CML) is a clonal disorder characterized by proliferation of cells expressing BCR-ABL fusion proteins. The BCR-ABL fusion proteins are tumor-specific antigens and represent reasonable targets for immunologic approaches against CML.; We have utilized a free-solution-isoelectric focusing technique (FS-IEF) to obtain chaperone rich cell lysates (CRCL) from tumors. We found that CRCL derived from 12B1, an aggressive bcr-abl+ murine tumor activated dendritic cells (DCs) by upregulating CD40 and MHC-II on their cell surface and stimulating them to produce interleukin-12 (IL-12). Vaccination of mice with 12B1 CRCL pulsed DCs generated potent, tumor specific, long lasting, CD4+ and CD8+ T cell dependent immune responses.; We have further demonstrated that immunization with 12B1 CRCL induced BCR-ABL specific cytotoxic T lymphocytes, indicating that BCR-ABL peptides are chaperoned by CRCL and are cross-presented to CD8+ T cells. Moreover, other antigenic peptides may also be present in the antigen repertoire of CRCL and contribute to the superior immunogenicity of 12B1-derived CRCL.; To better optimize immunity against CML, we investigated the effects of combining imatinib mesylate with 12B1 CRCL. Imatinib mesylate specifically inhibits BCR-ABL kinase activity and has been very successful in treating patients with CML. However, the development of drug resistance has led to drug combination approaches. We have shown that the combination of imatinib with DCs loaded with 12B1-derived CRCL yielded potent anti-tumor activity.; In addition to tumor-derived heat shock proteins, we have also studied the immunogenicity of apoptotic leukemic cells. We have previously reported that vaccination of mice with stressed apoptotic leukemic cells elicited potent anti-tumor immunity. We have found that stressed apoptotic leukemic cells, compared with non-stressed apoptotic ones, have higher capacity to upregulate CD40, CD80, and CD86 on the surface of DCs, to stimulate DCs to secrete IL-12, and to enhance their immunostimulatory functions in a mixed lymphocyte reaction (MLR). These findings demonstrate that apoptotic tumor cells can be immunogenic when stressed, and that DCs play a key role in determining whether a T cell response will be generated.
机译:慢性粒细胞性白血病(CML)是一种克隆性疾病,其特征是表达BCR-ABL融合蛋白的细胞增殖。 BCR-ABL融合蛋白是肿瘤特异性抗原,是针对CML的免疫学方法的合理靶标。我们已经利用自由溶液等电聚焦技术(FS-IEF)从肿瘤中获得了富分子伴侣的细胞裂解物(CRCL)。我们发现CRCL源自12B1,这是一种攻击性的 bcr-abl + 鼠肿瘤激活的树突状细胞(DC),它通过上调CD40和MHC-II在细胞表面的表达并刺激它们产生白介素12(IL-12)。用12B1 CRCL脉冲DC接种小鼠会产生有效的,肿瘤特异性的,持久的,CD4 + 和CD8 + T细胞依赖性免疫反应。我们进一步证明了用12B1 CRCL免疫诱导的BCR-ABL特异性细胞毒性T淋巴细胞,表明BCR-ABL肽被CRCL陪伴并交叉呈递至CD8 + T细胞。而且,其他抗原肽也可以存在于CRCL的抗原库中,并有助于12B1衍生的CRCL的优异免疫原性。为了更好地优化针对CML的免疫力,我们研究了甲磺酸伊马替尼与12B1 CRCL联合使用的效果。甲磺酸伊马替尼特异性抑制BCR-ABL激酶活性,在治疗CML患者方面非常成功。然而,耐药性的发展导致了药物组合方法。我们已经证明伊马替尼与负载12B1的CRCL的DC的结合产生有效的抗肿瘤活性。除了肿瘤衍生的热休克蛋白外,我们还研究了凋亡性白血病细胞的免疫原性。我们以前曾报道过,用重度凋亡的白血病细胞对小鼠进行疫苗接种会产生有效的抗肿瘤免疫力。我们发现,与非应激的凋亡白​​血病细胞相比,应激的凋亡白​​血病细胞具有更高的能力来上调DC表面的CD40,CD80和CD86,刺激DC分泌IL-12,并增强它们的免疫刺激功能。混合淋巴细胞反应(MLR)。这些发现表明,凋亡的肿瘤细胞在受到压力时可以具有免疫原性,并且DC在确定是否会产生T细胞应答中起关键作用。

著录项

  • 作者

    Zeng, Yi.;

  • 作者单位

    The University of Arizona.;

  • 授予单位 The University of Arizona.;
  • 学科 Health Sciences Immunology.; Health Sciences Oncology.
  • 学位 Ph.D.
  • 年度 2003
  • 页码 210 p.
  • 总页数 210
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 预防医学、卫生学;肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号